Gabapentinoids (eg pregabalin and gabapentin) are widely used in neurology, psychiatry
and primary healthcare but are increasingly being reported as possessing a potential for …

Introduction: Alcohol misuse is the fifth leading risk factor for premature death and disability
worldwide. Fewer than 10% of afflicted Americans receive pharmacological treatment for …

The British Association for Psychopharmacology guidelines for the treatment of substance
abuse, harmful use, addiction and comorbidity with psychiatric disorders primarily focus on …

Purpose Pregabalin is a novel GABA-analogue approved for the treatment of partial onset
seizures, neuropathic pain, and general anxiety disorder. Pregabalin has been classified as …

Background Alcohol use disorders (AUDs) are maladaptive patterns of alcohol consumption
manifested by symptoms leading to clinically significant impairment or distress. 1 Ethanol is …

Patients with alcohol-use disorders (AUDs) have a high prevalence of anxiety disorders
(AnxDs).“Co-occurring disorders” refers to the coexistence of an AUD and/or drug related …

Alcoholic patients suffer from harmful allostatic neuroplastic changes in the brain causing an
acute withdrawal syndrome upon cessation of drinking followed by a protracted abstinence …

The clinical interface between psychiatry and neurology is epilepsy; the pharmacological
expression of this interface is antiepileptic drugs (AEDs), as they are used to treat both …

Treatments for physical dependence and associated withdrawal symptoms following the
abrupt discontinuation of prescription drugs (such as opioids and benzodiazepines) …

Methods After detoxification, 52 patients were randomized into 2 groups as follows: 26
patients received 100 mg of TOP (oral, twice daily), titrated over 2 weeks, and 26 patients …